Jazz Pharmaceuticals (JAZZ.O): Final thoughts on 3Q: Ziihera early launch indicators impress; execution now takes center stage

Jazz delivered a strong 3Q, with revenue of $1.24B (+10% y/y) supported by oncology (+35% y/y), Xywav (+12% y/y) and Zepzelca (+32% y/y). Reflecting the broad-based commercial momentum, 2026 revenue guidance increased by ~$140M. Most importantly, Ziihera generated $21M and early cancer (GEA) launch indicators were encouraging: first-time ordering accounts tripled in September, 80% came from community practices and average vial demand per selling day increased ~40%. The launch remains early and persistence is not yet measurable, but reimbursement and pathway access appear smooth. Xywav also remains more durable than feared, with 425 net patient adds and limited generic impact. Modeyso delivered $61M, although $14M reflected Japan inventory, while Zepzelca faces a tougher 2027 competitive setup. Although JAZZ shares have outperformed YTD (+24% vs S&P 500; +10%), we remain buyers given improving Ziihera launch visibility, strong cash generation and potential upside from additional indicat